Prognostic and predictive factors for ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
Author(s) :
Lebellec, Loic [Auteur]
Bertucci, François [Auteur]
Institut Paoli-Calmettes [IPC]
Tresch-Bruneel, Emmanuelle [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ray-Coquard, Isabelle [Auteur]
Department of Medical Oncology [Lyon]
Centre Léon Bérard [Lyon]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Bompas, Emmanuelle [Auteur]
Centre René Gauducheau
CRLCC René Gauducheau
Blay, Jean-Yves [Auteur]
Centre Léon Bérard [Lyon]
Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL]
Italiano, Antoine [Auteur]
Mir, Olivier [Auteur]
Institut Gustave Roussy [IGR]
Ryckewaert, Thomas [Auteur]
Toiron, Yves [Auteur]
Institut Paoli-Calmettes [IPC]
Camoin, Luc [Auteur]
Institut Paoli-Calmettes [IPC]
Goncalves, Anthony [Auteur]
Institut Paoli-Calmettes [IPC]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Le Deley, Marie-Cécile [Auteur]
Université Paris-Saclay
Université Paris-Sud - Paris 11 [UP11]
Bertucci, François [Auteur]
Institut Paoli-Calmettes [IPC]
Tresch-Bruneel, Emmanuelle [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ray-Coquard, Isabelle [Auteur]
Department of Medical Oncology [Lyon]
Centre Léon Bérard [Lyon]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Bompas, Emmanuelle [Auteur]
Centre René Gauducheau
CRLCC René Gauducheau
Blay, Jean-Yves [Auteur]
Centre Léon Bérard [Lyon]
Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL]
Italiano, Antoine [Auteur]
Mir, Olivier [Auteur]
Institut Gustave Roussy [IGR]
Ryckewaert, Thomas [Auteur]
Toiron, Yves [Auteur]
Institut Paoli-Calmettes [IPC]
Camoin, Luc [Auteur]
Institut Paoli-Calmettes [IPC]
Goncalves, Anthony [Auteur]
Institut Paoli-Calmettes [IPC]
Penel, Nicolas [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Le Deley, Marie-Cécile [Auteur]
Université Paris-Saclay
Université Paris-Sud - Paris 11 [UP11]
Journal title :
BMC Cancer
Abbreviated title :
BMC Cancer
Volume number :
18
Pages :
963
Publication date :
2018-10-11
ISSN :
1471-2407
English keyword(s) :
Bevacizumab
Biomarkers
Weekly paclitaxel
Angiosarcoma
Radiation-induced angiosarcoma
Biomarkers
Weekly paclitaxel
Angiosarcoma
Radiation-induced angiosarcoma
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BACKGROUND: We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel.
METHODS: Circulating pro/anti-angiogenic factors were assessed on day 1 ...
Show more >BACKGROUND: We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. METHODS: Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival (PFS) was evaluated using a Cox model with biomarkers as continuous variables. RESULTS: Among the 51 patients enrolled and treated in this trial, biomarker analysis was performed for 42: 18 in Arm A (single-agent) and 24 in Arm B (combination). With a median follow-up of 46 months, PFS was 5.5 versus 5.7 months, respectively (p = 0.75). According to univariate analysis, factors associated with a poor PFS were as follows: visceral angiosarcoma, de novo angiosarcoma, and high PlGF and low VEGF-C baseline values. In multivariate analysis, de novo angiosarcoma (HR = 2.5; p = 0.024) and baseline VEGF-C value (HR = 0.7; p = 0.003) were significant prognostic factors. We observed a significant increase in circulating PlGF (< 0.001) and a decrease in VEGF (< 0.001) during bevacizumab treatment. An increase in FGF was associated with a poor outcome. CONCLUSIONS: De novo angiosarcoma and a low baseline level of VEGF-C were found to be associated with a poor prognosis. Addition of bevacizumab induces major changes in circulating biomarkers (VEGF and PlGF) in a short timeframe without impacting PFS. BACKGROUND: Retrospectively registered on EudraCT N° 2009-017020-59 and NCT01303497 (February 24, 2011).Show less >
Show more >BACKGROUND: We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. METHODS: Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival (PFS) was evaluated using a Cox model with biomarkers as continuous variables. RESULTS: Among the 51 patients enrolled and treated in this trial, biomarker analysis was performed for 42: 18 in Arm A (single-agent) and 24 in Arm B (combination). With a median follow-up of 46 months, PFS was 5.5 versus 5.7 months, respectively (p = 0.75). According to univariate analysis, factors associated with a poor PFS were as follows: visceral angiosarcoma, de novo angiosarcoma, and high PlGF and low VEGF-C baseline values. In multivariate analysis, de novo angiosarcoma (HR = 2.5; p = 0.024) and baseline VEGF-C value (HR = 0.7; p = 0.003) were significant prognostic factors. We observed a significant increase in circulating PlGF (< 0.001) and a decrease in VEGF (< 0.001) during bevacizumab treatment. An increase in FGF was associated with a poor outcome. CONCLUSIONS: De novo angiosarcoma and a low baseline level of VEGF-C were found to be associated with a poor prognosis. Addition of bevacizumab induces major changes in circulating biomarkers (VEGF and PlGF) in a short timeframe without impacting PFS. BACKGROUND: Retrospectively registered on EudraCT N° 2009-017020-59 and NCT01303497 (February 24, 2011).Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Université de Lille
Université de Lille
Submission date :
2019-12-09T18:19:22Z
2020-04-01T13:53:17Z
2020-04-03T08:44:43Z
2020-04-01T13:53:17Z
2020-04-03T08:44:43Z
Files
- Prognostic and predictive factors.pdf
- Version éditeur
- Open access
- Access the document